S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:ADXN

Addex Therapeutics (ADXN) Stock Price, News & Analysis

$11.99
+0.28 (+2.39%)
(As of 03/18/2024 ET)
Today's Range
$11.45
$11.99
50-Day Range
$6.45
$13.10
52-Week Range
$5.00
$25.60
Volume
7,592 shs
Average Volume
10,570 shs
Market Capitalization
$11.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Addex Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Addex Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($17.20) to ($11.80) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.36 out of 5 stars

Medical Sector

923rd out of 947 stocks

Pharmaceutical Preparations Industry

425th out of 435 stocks

ADXN stock logo

About Addex Therapeutics Stock (NASDAQ:ADXN)

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

ADXN Stock Price History

ADXN Stock News Headlines

8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)
THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here:
Addex to Present at Biotech Showcase™ 2024
Addex Therapeutics Ltd
My next big prediction isn’t a prediction
I believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.
Addex Creates Treasury Shares
Addex Therapeutics Posts Narrower Loss In Q3 - Quick Facts
Addex Convenes Extraordinary General Meeting
Addex Therapeutics: Addex Completes ADS Ratio Change
Addex Completes ADS Ratio Change
Addex To Implement ADS Ratio Change
H.C. Wainwright Reaffirms Their Hold Rating on Addex Therapeutics (ADXN)
See More Headlines
Receive ADXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/18/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADXN
Employees
24
Year Founded
N/A

Profitability

Net Income
$-21,800,000.00
Net Margins
-550.78%
Pretax Margin
-549.49%

Debt

Sales & Book Value

Annual Sales
$2.05 million
Book Value
$8.01 per share

Miscellaneous

Free Float
843,000
Market Cap
$11.85 million
Optionable
Not Optionable
Beta
1.62
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Timothy Mark Dyer (Age 56)
    Co-Founder, CEO & Director
  • Dr. Roger G. Mills M.D. (Age 67)
    Chief Medical Officer & Director
  • Mr. Lénaic Teyssédou (Age 38)
    Head of Finance
  • Dr. Jean-Philippe Rocher Ph.D. (Age 65)
    Head of Discovery - Chemistry
  • Dr. Robert Lutjens (Age 56)
    Head of Discovery - Biology
  • Dr. Mikhail Kalinichev Ph.D. (Age 57)
    Head of Translational Science

ADXN Stock Analysis - Frequently Asked Questions

Should I buy or sell Addex Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares.
View ADXN analyst ratings
or view top-rated stocks.

How have ADXN shares performed in 2024?

Addex Therapeutics' stock was trading at $6.05 at the beginning of 2024. Since then, ADXN stock has increased by 98.2% and is now trading at $11.99.
View the best growth stocks for 2024 here
.

Are investors shorting Addex Therapeutics?

Addex Therapeutics saw a increase in short interest in February. As of February 29th, there was short interest totaling 8,400 shares, an increase of 33.3% from the February 14th total of 6,300 shares. Based on an average daily volume of 9,600 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.8% of the shares of the company are short sold.
View Addex Therapeutics' Short Interest
.

When is Addex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ADXN earnings forecast
.

How were Addex Therapeutics' earnings last quarter?

Addex Therapeutics Ltd (NASDAQ:ADXN) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($14.40) EPS for the quarter, hitting analysts' consensus estimates of ($14.40). The firm had revenue of $0.83 million for the quarter, compared to analyst estimates of $0.42 million. Addex Therapeutics had a negative trailing twelve-month return on equity of 236.83% and a negative net margin of 550.78%. During the same period last year, the business posted ($15.60) EPS.

When did Addex Therapeutics' stock split?

Addex Therapeutics shares reverse split before market open on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Addex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

Who are Addex Therapeutics' major shareholders?

Addex Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include J. Stern & Co. LLP (10.89%) and Armistice Capital LLC (4.34%).

How do I buy shares of Addex Therapeutics?

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXN) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners